Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

Rhea-AI Summary

Corcept Therapeutics (NASDAQ: CORT) will report its first quarter financial results and provide a corporate update on May 6, 2021. A conference call is scheduled for the same day at 5:00 p.m. ET (2:00 p.m. PT). The call will allow participants to discuss the financials and updates directly with the management team. Additionally, a replay of the call will be available until May 20, 2021. Corcept specializes in developing drugs targeting severe metabolic, oncologic, and psychiatric disorders by modulating cortisol effects, with its drug Korlym approved for Cushing’s syndrome.

Positive

• Scheduled financial results and corporate update on May 6, 2021.
• Korlym approved by FDA for Cushing's syndrome, indicating a successful product.

Negative

• None.

MENLO PARK, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 6, 2021. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

Conference Call Information
To participate, click the link below and enter your information. The link will become active 15 minutes prior to the scheduled start time.

Click to Join Meeting

Alternatively, you may dial 1-888-204-4368 from the United States or 1-313-209-4906 internationally approximately 15 minutes before the start of the call. The passcode will be 8720277.

A replay will be available through May 20, 2021 at 1-888-203-1112 from the United States and 1-719-457-0820 internationally. The passcode will be 8720277.

About Corcept Therapeutics Incorporated

Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym^® was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s syndrome. Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol. The company owns extensive United States and foreign intellectual property covering the composition of its selective cortisol modulators and the use of cortisol modulators to treat a variety of serious disorders.

CONTACT:
Corcept Therapeutics
Investor Relations
ir@corcept.com
www.corcept.com

FAQ

When will Corcept Therapeutics report its financial results for Q1 2021?

Corcept Therapeutics will report its financial results on May 6, 2021.

What time is Corcept Therapeutics' conference call on May 6, 2021?

The conference call is scheduled for 5:00 p.m. ET on May 6, 2021.

What is Korlym, and what is its significance for Corcept Therapeutics?

Korlym is the first drug approved by the FDA for treating Cushing's syndrome, which showcases Corcept's success in drug development.

How can I participate in Corcept Therapeutics' conference call?

You can participate by clicking the provided link or by dialing 1-888-204-4368 in the U.S. approximately 15 minutes before the call.

Will there be a replay of the conference call?

Yes, a replay of the conference call will be available until May 20, 2021.